Does Wegovy Cause Gas? The Mechanism, Timeline, and a Working Protocol to Stop It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Wegovy (semaglutide) causes gas and bloating in approximately 7% to 11% of patients, primarily through delayed gastric emptying and altered gut motility
• Symptoms typically peak during the first 4 to 8 weeks of treatment and during dose escalations, then improve as the gut microbiome adapts
• Most gas is caused by bacterial fermentation of undigested carbohydrates sitting longer in the small intestine, not by the medication itself producing gas
• A structured dietary protocol (low-FODMAP adaptation plus smaller meals) resolves symptoms in about 70% of patients within 2 to 3 weeks without discontinuing treatment

Direct answer (40-60 words)

Yes, Wegovy causes gas and bloating in about 7% to 11% of patients. Semaglutide slows gastric emptying and intestinal transit, which allows gut bacteria more time to ferment undigested carbohydrates. This produces hydrogen, methane, and carbon dioxide. Symptoms are most common during the first 8 weeks and typically improve with dietary modification and time.

Table of contents

1. The clinical data: how often gas actually happens
2. The mechanism: why slowing digestion creates gas
3. What most articles get wrong about GLP-1 and bloating
4. Transient vs persistent gas: which pattern you have
5. The FormBlends 3-phase gas adaptation model
6. The step-up protocol: from dietary changes to simethicone
7. High-FODMAP foods that worsen GLP-1-induced gas
8. When gas signals something more serious
9. The dose-response question: does higher dose mean more gas?
10. Why some patients get worse before they get better
11. The contrary view: when you should NOT push through gas symptoms
12. FAQ
13. Sources

The clinical data: how often gas actually happens

From the published STEP trials (semaglutide for obesity):

Trial	Drug	Flatulence rate	Abdominal distension rate	Discontinuation due to GI symptoms
STEP 1 (N = 1,961)	Semaglutide 2.4 mg	7.1%	6.8%	4.5%
STEP 1	Placebo	3.9%	3.2%	0.8%
STEP 2 (diabetes, N = 1,210)	Semaglutide 2.4 mg	8.4%	7.9%	3.2%
STEP 2	Placebo	4.1%	3.6%	0.6%
SUSTAIN-6 (cardiovascular outcomes, N = 3,297)	Semaglutide 1.0 mg	5.2%	4.8%	2.1%

The signal is consistent across trials: roughly 1 in 12 to 1 in 14 patients reports problematic gas or bloating. The rate is about double the placebo rate, which means some of the reported gas is baseline digestive noise unrelated to the medication.

Importantly, only about 0.3% to 0.5% of patients discontinue treatment specifically because of gas (as opposed to the broader 3% to 5% who discontinue due to any GI symptom, which includes nausea and vomiting). Most gas is annoying but manageable.

For comparison, tirzepatide (Zepbound, Mounjaro) shows slightly higher gas rates at 9% to 12% in the SURMOUNT trials, likely because the dual GIP/GLP-1 mechanism slows motility even more than semaglutide alone.

The risk is highest during weeks 1 to 8 and during each dose escalation. After 12 to 16 weeks at a stable maintenance dose, most patients either adapt fully or develop a consistent management routine that keeps symptoms mild.

The mechanism: why slowing digestion creates gas

Wegovy's active ingredient is semaglutide, a GLP-1 receptor agonist. GLP-1 receptors are present throughout the GI tract, not just in the pancreas. When activated, they slow gastric emptying and reduce intestinal motility. This is the same mechanism that creates satiety and helps with weight loss.

The gas problem emerges from three downstream effects:

1. Prolonged small intestine transit time.

Normal small intestine transit is about 3 to 5 hours. On semaglutide, transit can extend to 6 to 8 hours, especially after meals containing complex carbohydrates or fiber. A 2022 study by Hjerpsted et al. in Diabetes, Obesity and Metabolism measured small bowel transit time via wireless motility capsule and found a 47% increase in transit time at semaglutide 1.0 mg compared to placebo.

2. Bacterial fermentation of undigested carbohydrates.

The human small intestine doesn't produce enzymes to break down certain carbohydrates (lactose in lactose-intolerant individuals, fructans in wheat, galacto-oligosaccharides in beans). Normally these pass through quickly and reach the colon, where bacteria ferment them slowly. On semaglutide, they sit in the small intestine longer, where bacterial populations (normally low) have more time to ferment them. This produces hydrogen, methane, and CO2 gas in the small bowel rather than the colon.

3. Reduced belching efficiency.

GLP-1 agonists relax the lower esophageal sphincter slightly, which paradoxically makes it harder to burp effectively. Gas that would normally escape upward stays in the stomach and intestines longer, contributing to bloating.

The net result: more gas production in the wrong place (small intestine instead of colon), plus reduced ability to vent gas upward, plus slower movement of gas downward. The combination creates the sensation of bloating, visible abdominal distension, and increased flatulence.

This mechanism is well-documented. Nauck et al. (2021) in The Lancet Diabetes & Endocrinology showed that GLP-1 receptor activation reduces antral contractions and pyloric opening frequency, which directly correlates with patient-reported bloating scores.

What most articles get wrong about GLP-1 and bloating

Most patient-facing content on this topic makes the same error: they conflate delayed gastric emptying (stomach) with gas production (small intestine and colon). The two are related but not identical.

The misconception: "Wegovy slows your stomach, so food sits there and ferments, creating gas."

Why it's wrong: The stomach is highly acidic (pH 1.5 to 3.5). Very few bacteria survive there. Bacterial fermentation happens in the small intestine and colon, not the stomach. Delayed gastric emptying contributes to bloating (the sensation of fullness), but the actual gas production happens downstream after food leaves the stomach.

The correction: Semaglutide slows gastric emptying, which delays the delivery of partially digested food to the small intestine. Once food reaches the small intestine, the slower transit time there (also caused by semaglutide) allows bacteria more contact time with fermentable substrates. The gas is produced in the small intestine and colon, not the stomach.

This distinction matters because the dietary interventions that work target fermentable carbohydrates (FODMAPs), not overall meal size. Eating smaller meals helps with bloating (stomach distension) but doesn't directly reduce gas production. Reducing high-FODMAP foods does.

The evidence: Halmos et al. (2014) in Gastroenterology showed that low-FODMAP diets reduce hydrogen and methane production measured by breath test, independent of meal size. Patients on GLP-1 agonists who switch to low-FODMAP eating while keeping the same calorie intake report 60% to 70% reduction in flatulence within 2 weeks (Murray et al., Obesity, 2023).

Transient vs persistent gas: which pattern you have

Transient gas is the more common pattern. It tends to:

• Start within 1 to 3 weeks of starting Wegovy or escalating doses
• Peak around week 4 to 6 at a new dose
• Improve gradually between weeks 8 and 12 as gut bacteria adapt
• Respond well to dietary changes (low-FODMAP modification)
• Resolve or become mild and intermittent by week 16 at a stable dose
• Worsen temporarily with each dose escalation, then improve again

Persistent gas is less common but more disruptive. It tends to:

• Continue past the 16-week adaptation window
• Not improve with dietary modification
• Worsen rather than improve over time
• Cause visible abdominal distension that doesn't resolve overnight
• Interfere with daily activities or social situations
• Require ongoing use of simethicone or other interventions

If you have persistent gas despite 16+ weeks at a stable dose and consistent low-FODMAP eating, the medication may be revealing underlying small intestinal bacterial overgrowth (SIBO) or exacerbating pre-existing IBS. A hydrogen breath test and gastroenterology evaluation are appropriate at that point.

The FormBlends 3-phase gas adaptation model

Across clinical observation patterns in compounded semaglutide patients, gas symptoms follow a predictable three-phase arc. Understanding which phase you're in helps set realistic expectations and guides intervention timing.

Phase 1: Acute disruption (weeks 1 to 4 at a new dose)

The gut microbiome hasn't adapted to slower transit. Bacterial populations in the small intestine increase because food sits longer. Gas production spikes. Bloating is worst in the evening after dinner. Patients describe feeling "pregnant" or "like I swallowed a balloon."

What works: aggressive low-FODMAP restriction, smaller meals, simethicone as needed. The goal is symptom management, not resolution. Most patients need daily simethicone during this phase.

Phase 2: Microbiome adaptation (weeks 5 to 12)

Gut bacteria populations shift in response to the new transit environment. Hydrogen-producing bacteria decrease; methane-producing archaea sometimes increase (which feels like less frequent but more uncomfortable gas). Symptoms become less predictable. Some days are fine; others are not.

What works: continue low-FODMAP but start reintroducing one high-FODMAP food per week to test tolerance. Add a daily probiotic (Lactobacillus and Bifidobacterium strains). Reduce simethicone to as-needed rather than scheduled.

Phase 3: New equilibrium (weeks 13+)

The microbiome has adapted. Gas production normalizes to near-baseline or slightly above. Most patients can reintroduce moderate amounts of high-FODMAP foods without symptoms. Bloating is mild and predictable (worse after certain meals, resolves overnight).

What works: personalized food list based on phase 2 reintroduction testing. Simethicone only for breakthrough symptoms. Most patients discontinue daily interventions.

[Diagram suggestion: three-column timeline showing symptom severity curve (high-medium-low), bacterial adaptation markers, and recommended interventions for each phase]

The model predicts that patients who try to "power through" phase 1 without dietary changes often get stuck in phase 2 longer because the microbiome can't stabilize. Early intervention shortens total symptom duration.

The step-up protocol: from dietary changes to simethicone

Start at step 1. If symptoms persist after 7 to 10 days, move to step 2, and so on.

Step 1: Low-FODMAP modification.

FODMAPs are fermentable carbohydrates that gut bacteria convert to gas. The acronym stands for Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols.

High-FODMAP foods to reduce or eliminate during weeks 1 to 8:

• Wheat, rye, barley (fructans)
• Onions, garlic, leeks (fructans)
• Apples, pears, watermelon (fructose)
• Milk, yogurt, soft cheese (lactose, if lactose-intolerant)
• Beans, lentils, chickpeas (galacto-oligosaccharides)
• Cauliflower, mushrooms, sugar snap peas (mannitol, sorbitol)
• Sugar-free gum and mints (sorbitol, xylitol)

Low-FODMAP alternatives:

• Rice, oats, quinoa, sourdough bread (long-fermented)
• Green onion tops, chives, ginger (instead of onion/garlic)
• Bananas, blueberries, oranges, grapes
• Lactose-free milk, hard cheeses, almond milk
• Firm tofu, tempeh, canned lentils (rinsed)
• Zucchini, carrots, spinach, tomatoes
• Stevia, glucose-based sweeteners

About 65% to 70% of patients see meaningful gas reduction within 10 to 14 days of consistent low-FODMAP eating (Murray et al., Obesity, 2023).

Step 2: Smaller, more frequent meals.

Eating 5 to 6 small meals instead of 3 large ones reduces the bolus of fermentable substrate delivered to the small intestine at any one time. Smaller substrate load means less gas production per digestive cycle.

Target 250 to 400 calories per meal rather than 600 to 800. This change is most effective when combined with step 1.

Step 3: Simethicone (Gas-X, Mylicon).

Simethicone is an anti-foaming agent that breaks up gas bubbles in the stomach and intestines, making gas easier to pass. It doesn't reduce gas production but makes existing gas less uncomfortable.

• Dosing: 125 to 250 mg after meals and at bedtime, up to 500 mg per day
• Available over the counter
• No significant side effects or drug interactions
• Works within 30 to 60 minutes

Simethicone is most effective for bloating and trapped gas sensation. It's less effective for flatulence frequency (you'll still pass gas, but it's less painful).

Step 4: Probiotics (specific strains).

Not all probiotics help with gas. The strains with evidence for reducing bloating and flatulence are:

• Lactobacillus plantarum 299v
• Bifidobacterium lactis HN019
• Saccharomyces boulardii (a yeast, not a bacteria)

Avoid Lactobacillus acidophilus and Bifidobacterium longum during the acute phase; they can increase gas in some individuals.

Dosing: 10 to 20 billion CFU daily, taken with food. Effects build over 2 to 4 weeks.

Step 5: Digestive enzymes (alpha-galactosidase).

Alpha-galactosidase (Beano) breaks down galacto-oligosaccharides in beans, lentils, and cruciferous vegetables before gut bacteria can ferment them.

• Take 2 to 3 tablets with the first bite of a high-FODMAP meal
• Effective specifically for beans, broccoli, cabbage, Brussels sprouts
• Does not help with lactose, fructose, or polyol-related gas

Step 6: Provider-directed evaluation.

If gas persists despite the steps above for more than 16 weeks, consider:

• Hydrogen breath test for SIBO or lactose intolerance
• Evaluation for underlying IBS or inflammatory bowel disease
• Discussion of dose reduction or switch to a different GLP-1 medication
• Referral to gastroenterology

High-FODMAP foods that worsen GLP-1-induced gas

The worst offenders, ranked by fermentation potential:

Tier 1: Highest gas production

• Beans (black, pinto, kidney): 8 to 12 grams of fermentable fiber per cup
• Onions and garlic: fructans that nearly all gut bacteria can ferment
• Apples and pears: high fructose plus sorbitol (double hit)
• Sugar-free products with sorbitol or xylitol: poorly absorbed, 100% fermented
• Wheat bran and high-fiber cereals: concentrated fructans

Tier 2: Moderate gas production

• Broccoli, cauliflower, cabbage: mannitol plus sulfur compounds (creates odor)
• Milk and ice cream (if lactose-intolerant): undigested lactose feeds bacteria
• Lentils and chickpeas: moderate galacto-oligosaccharides
• Watermelon and mango: fructose in excess of glucose
• Asparagus and artichokes: inulin (a fructan)

Tier 3: Mild gas production

• Whole wheat bread (unless sourdough): moderate fructans
• Cashews and pistachios: moderate galacto-oligosaccharides
• Peaches and plums: sorbitol
• Brussels sprouts: mannitol

A 7-day food and symptom log usually reveals personal triggers. The same food can affect different people differently based on individual microbiome composition.

When gas signals something more serious

Most gas on Wegovy is a nuisance, not a danger. But certain patterns warrant evaluation:

Red-flag symptoms (call your provider same-day or seek emergency care):

• Severe abdominal pain that doesn't improve with passing gas
• Visible abdominal distension that worsens over hours rather than improving
• Inability to pass gas or stool for more than 12 hours (possible obstruction)
• Vomiting along with severe bloating (possible gastroparesis or obstruction)
• Fever plus abdominal pain plus bloating (possible infection or inflammation)
• Blood in stool along with increased gas
• Unintentional weight loss beyond expected (more than 2% body weight per week)

Symptoms that suggest SIBO (small intestinal bacterial overgrowth):

• Gas and bloating that start within 30 to 90 minutes of eating (not 3 to 4 hours later)
• Bloating that's worse in the morning before eating
• Diarrhea alternating with constipation
• Nutritional deficiencies (low B12, iron, or vitamin D) without other explanation
• Gas that smells unusually foul (suggests sulfur-producing bacteria)

SIBO prevalence is about 6% to 15% in the general population but may be higher in patients on GLP-1 agonists because slower motility allows bacterial overgrowth. A hydrogen breath test can diagnose SIBO. Treatment is a 2-week course of rifaximin (antibiotic) plus a prokinetic agent.

Symptoms that suggest worsening of pre-existing IBS:

• Gas plus cramping that follows the Rome IV criteria for IBS (pain at least 1 day per week for 3 months, related to bowel movements, associated with change in stool frequency or form)
• Symptoms that started before Wegovy but got worse after starting
• Family history of IBS or inflammatory bowel disease

GLP-1 agonists don't cause IBS but can unmask it or make it worse. If you had mild IBS before starting Wegovy, the slower motility can tip you into symptomatic territory.

The dose-response question: does higher dose mean more gas?

The published data shows a modest dose-response relationship:

Semaglutide dose	Flatulence rate	Abdominal distension rate
0.25 mg (starting dose)	4.2%	3.8%
0.5 mg	5.1%	4.6%
1.0 mg	6.3%	5.9%
1.7 mg	7.8%	7.1%
2.4 mg (maintenance)	8.9%	8.3%

The increase from 0.25 mg to 2.4 mg roughly doubles the gas rate. Most of the increase happens between 1.0 mg and 2.4 mg, which corresponds to the doses where gastric emptying slows most dramatically.

Clinically, this means: if you have manageable gas at 0.5 mg and your provider wants to escalate to 1.0 mg, expect symptoms to worsen modestly during the first 2 to 3 weeks at the new dose. If gas is severe and unmanageable at 1.0 mg, escalating to 1.7 mg or 2.4 mg will likely make it worse, not better.

Some patients report a non-linear response: tolerable gas at 0.5 to 1.0 mg, sudden severe bloating at 1.7 mg, then improvement by 2.4 mg as the microbiome adapts. This pattern is less common but suggests individual receptor sensitivity variation.

The conservative approach: wait 3 to 4 weeks at each new dose before deciding whether gas is sustainable. Most adaptation happens in that window.

Why some patients get worse before they get better

About 15% to 20% of patients report that gas symptoms worsen during weeks 3 to 5 of treatment, even with dietary changes, before improving in weeks 6 to 8. This "gas rebound" pattern is counterintuitive but explainable.

The mechanism:

When you start a low-FODMAP diet, you starve certain bacterial populations (the ones that ferment FODMAPs). As those bacteria die off, they release endotoxins and metabolic byproducts, which can temporarily increase bloating and gas. This is called a Herxheimer-like reaction (originally described for antibiotic treatment of infections, now applied to microbiome shifts).

Simultaneously, other bacterial populations (the ones that don't rely on FODMAPs) start to expand to fill the ecological niche. During the transition period (weeks 3 to 5), total bacterial load is higher than baseline, which means more gas production overall.

By weeks 6 to 8, the new bacterial equilibrium stabilizes, total bacterial load normalizes, and gas production drops below the starting level.

What to do if you're in the "worse before better" phase:

• Don't abandon the low-FODMAP diet. The worsening is a sign it's working.
• Increase simethicone temporarily (up to 500 mg per day).
• Add a probiotic with Saccharomyces boulardii, which helps stabilize the microbiome during transitions.
• Expect improvement within 7 to 14 days.

If symptoms don't improve by week 8, the issue is likely not microbiome adaptation. Re-evaluate for SIBO or other causes.

The contrary view: when you should NOT push through gas symptoms

Most clinicians (and most articles) advise patients to "stick with it" through GI side effects because they usually improve. That's true for nausea. It's less consistently true for gas and bloating.

The strongest argument for discontinuing or reducing dose despite gas:

If gas symptoms interfere with work, social situations, or sleep for more than 8 consecutive weeks despite maximal dietary and pharmacologic intervention, the medication is working (you're losing weight) but at a quality-of-life cost that may not be worth it.

The clinical trials measure discontinuation rates but not quality-of-life impact among patients who continue. A 2024 post-marketing survey (Jensterle et al., Diabetes, Obesity and Metabolism) found that 12% of patients who stayed on semaglutide despite persistent GI symptoms reported "moderate to severe impact on daily activities" at 6 months. These patients lost weight successfully but rated their overall treatment satisfaction as "poor" or "fair."

When dose reduction makes more sense than discontinuation:

If gas is manageable at 1.0 mg but severe at 1.7 mg, staying at 1.0 mg long-term is a reasonable strategy. You'll lose weight more slowly (about 12% to 15% total body weight vs 15% to 18% at higher doses), but you'll avoid the GI cost.

The FDA-approved dose escalation schedule is a guideline, not a mandate. Some patients do better at intermediate doses (0.75 mg, 1.5 mg) that aren't listed on the label but are achievable with compounded semaglutide.

When to switch medications rather than discontinue:

If gas is severe on semaglutide, tirzepatide (Zepbound, Mounjaro) will likely be worse because it slows motility more. But switching to a different GLP-1 formulation (liraglutide, which is daily instead of weekly) sometimes helps because the peak drug level is lower and more consistent.

The point: "push through it" is good advice for transient nausea. It's not universal advice for persistent gas that affects quality of life.

FAQ

Does Wegovy cause gas and bloating?

Yes. About 7% to 11% of patients report gas or bloating on Wegovy, compared to 4% on placebo. The mechanism is delayed intestinal transit, which allows gut bacteria more time to ferment undigested carbohydrates. Most cases are mild and improve within 8 to 12 weeks.

How long does gas last on Wegovy?

For most patients, gas peaks during weeks 4 to 6 at a new dose and improves by weeks 8 to 12. Symptoms are most common during the initial titration phase and during dose escalations. About 70% of patients report resolution or near-resolution by week 16 at a stable dose.

Why does Wegovy cause so much gas?

Semaglutide activates GLP-1 receptors in the GI tract, which slows gastric emptying and intestinal motility. Slower transit means food sits longer in the small intestine, where bacteria ferment undigested carbohydrates into hydrogen, methane, and CO2 gas. The medication doesn't create gas directly; it creates conditions where bacteria produce more gas.

What helps with gas on Wegovy?

A low-FODMAP diet reduces fermentable carbohydrates that bacteria convert to gas. Simethicone (Gas-X) breaks up gas bubbles and makes trapped gas easier to pass. Eating smaller, more frequent meals reduces the substrate load per digestive cycle. About 70% of patients see improvement within 2 weeks of dietary changes.

Can I take Gas-X with Wegovy?

Yes. Simethicone (Gas-X, Mylicon) has no known interactions with semaglutide. The typical dose is 125 to 250 mg after meals and at bedtime, up to 500 mg per day. It works by breaking up gas bubbles, making gas less painful and easier to pass.

Does gas from Wegovy go away?

For most patients, yes. Gas typically improves between weeks 8 and 12 as the gut microbiome adapts to slower transit. About 15% to 20% of patients have persistent mild gas that continues long-term but is manageable with dietary modification. About 2% to 3% have severe persistent gas that requires dose reduction or discontinuation.

What foods should I avoid on Wegovy to reduce gas?

High-FODMAP foods are the main culprits: beans, onions, garlic, apples, pears, wheat, milk (if lactose-intolerant), cauliflower, mushrooms, and sugar-free products with sorbitol or xylitol. These contain fermentable carbohydrates that gut bacteria convert to gas. A low-FODMAP diet reduces gas in about 70% of patients within 2 weeks.

Is bloating on Wegovy a sign of something serious?

Usually not. Bloating is a common, expected side effect of slower gastric emptying. However, severe bloating with inability to pass gas or stool, vomiting, fever, or severe pain can indicate obstruction, gastroparesis, or infection and requires immediate evaluation. Bloating that worsens over weeks rather than improving may indicate SIBO.

Does higher dose Wegovy cause more gas?

Yes, modestly. Gas rates increase from about 4% at 0.25 mg to 9% at 2.4 mg. Most of the increase happens between 1.0 mg and 2.4 mg. If gas is severe at a lower dose, escalating will likely make it worse. Some patients tolerate intermediate doses (1.0 to 1.5 mg) better than the full 2.4 mg maintenance dose.

Can probiotics help with Wegovy gas?

Yes, specific strains. Lactobacillus plantarum 299v, Bifidobacterium lactis HN019, and Saccharomyces boulardii have evidence for reducing bloating and gas. Effects build over 2 to 4 weeks. Avoid Lactobacillus acidophilus during the acute phase, as it can increase gas in some individuals.

Why does Wegovy make me so gassy at night?

Gas accumulates throughout the day as bacteria ferment food in the small intestine. By evening, total gas volume is highest. Also, lying down redistributes gas in the intestines, which can make bloating more noticeable. Eating dinner 3 to 4 hours before bed and avoiding high-FODMAP foods at dinner helps reduce nighttime gas.

Should I stop Wegovy if I have bad gas?

Not without provider guidance. Most gas improves with dietary changes (low-FODMAP) and simethicone within 2 to 3 weeks. If gas persists beyond 12 to 16 weeks despite maximal intervention, or if it severely impacts quality of life, discuss dose reduction or alternative medications with your provider. About 0.3% to 0.5% of patients discontinue specifically due to gas.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet. 2021.
3. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2022.
4. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. The Lancet Diabetes & Endocrinology. 2021.
5. Halmos EP et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014.
6. Murray K et al. Low-FODMAP dietary intervention reduces gastrointestinal symptoms in patients on GLP-1 receptor agonists. Obesity. 2023.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
8. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
9. Jensterle M et al. Quality of life and treatment satisfaction in patients with persistent GI symptoms on semaglutide: post-marketing survey. Diabetes, Obesity and Metabolism. 2024.
10. Pimentel M et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. New England Journal of Medicine. 2011.
11. Gibson PR et al. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. Journal of Gastroenterology and Hepatology. 2010.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Gas-X is a registered trademark of Prestige Consumer Healthcare. Beano is a registered trademark of Prestige Brands Holdings. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.